Much to the delight, recent disclosures perspicuously underscore the favourable trends witnessed with PARP inhibitors in endometrial cancer such as: (i) the promising efficacy of olaparib in advanced endometrial carcinoma31 (ii) pathologic complete response of high-grade endometrial cancer to PARP inhibitors32 (iii) optimistic activity profile of a triplet regimen consisting of PARP inhibitor in recurrent, advanced endometrial carcinoma33 (iv) manifestation of efficacy by olaparib, in cultured endometrial carcinoma cells.34 The gene discussed is PARP1; the disease is endometrial carcinoma.